Recent news on Infergen

Valeant Pharmaceuticals Reports 2007 First Quarter Results  -  May 1, 2007
Genetic Engineering News (press release),The decrease in sales of Infergen largely reflects a decline in the overall market for interferon products in the United States. The decline in Efudex sales

Valeant Pharmaceuticals Reports 2007 First Quarter Results  -  May 1, 2007
Business Wire (press release),In addition, sales of Infergen and Efudex were lower in the 2007 first quarter, while sales of Cesamet®, Kinerase®, Solcoseryl™ and Bisocard™ were higher.

MIGENIX to Present Celgosivir Phase II Hepatitis C Results at ...  -  May 18, 2007
CNW Telbec (Communiqués de presse),...celgosivir has shown excellent in vitro synergy with various interferons in the clinic or in development including Pegasys, PEG-Intron, Infergen,

EXECUTIVE SUMMARY  -  May 5, 2007
Orange County Business Journal,The company attributed the decline to lower sales to Mexican wholesalers and lower sales of Infergen for the declines. Santa Ana’s First American Corp.

Medical Breakthrough -- Hep C Help  -  Apr 11, 2007
WQAD,..."Re-treatment with Infergen at a daily does can render an additional 25 percent of these resistant patients virus undetectable," says Dr. Shiffman.

New Clinical Study Results Indicate Higher Early Virologic ...  -  Apr 13, 2007
Drug Newswire (press release),...celgosivir has shown excellent in vitro synergy with various interferons in the clinic or in development including Pegasys, PEG-Intron, Infergen,

Help for Hep C  -  27 Mar 2007
ABC30.com,..."Re-treatment with Infergen at a daily does can render an additional 25 percent of these resistant patients virus undetectable," Dr. Shiffman,

Hep C Help  -  Mar 20, 2007
WFtv.com,Infergen is an interferon that has a much higher potency than other interferons. In a study Dr. Shiffman found about 25 percent of people who had failed

Valeant Pharmaceuticals Reports Fourth Quarter and Full-Year 2006 ...  -  Feb 28, 2007
Genetic Engineering News (press release),Product sales improvements in the fourth quarter and full year were led by the acquisition of Infergen(R), the launch of Zelapar(R) and growth in key

TABLE-Valeant more than halves Q4 net loss  -  Feb 28, 2007
Reuters...it recorded a charge of $5.2 million due to cost of goods sold in the 2006 fourth quarter for the transfer of manufacturing technology for Infergen.

Hep C Help  -  Feb 21, 2007
WTVF,..."Re-treatment with Infergen at a daily does can render an additional 25 percent of these resistant patients virus undetectable," Shiffman said.

Help for hepatitis C  -  Feb 8, 2007
News 8 Austin,Infergen is an interferon that has a much higher potency than other interferons. In a study Shiffman found about 25 percent of people who had failed

InterMune Announces Fourth Quarter and Full Year 2006 Financial ...  -  Feb 9, 2007
PharmaLive.com (press release),As a result of the December 30, 2005, divestiture of Infergen(R) and in compliance with US Generally Accepted Accounting Principals (GAAP),

Valeant Pharmaceuticals Initiates Infergen Phase 4 Study  -  Dec 12, 2006
PharmaLive.com (press release),The study will evaluate the use of Infergen 15 ug/day plus ribavirin (1.0-1.2 g/day) in patients who did not have an optimal response at week 12 of

Valeant Begins Fourth Phase Infergen Trials  -  Dec 12, 2006
Orange County Business Journal,Valeant Pharmaceuticals International said Tuesday that it started a fourth-phase clinical trial of hepatitis C drug Infergen in combination with ribavirin

Market Report -- In Play (WIRES)  -  Dec 12, 2006
MSN MoneyValeant Pharmaceuticals (VRX) announces its plans to initiate a phase 4 study of Infergen... Biomira (BIOM) announces that it has reached an agreement with

EXECUTIVE SUMMARY  -  Dec 16, 2006
Orange County Business Journal,Valeant Pharmaceuticals International said last week that it started a fourth-phase clinical trial of hepatitis C drug Infergen with ribavirin for treating

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional